MicroRNA-132-3p (miR-132-3p) (miR-132-3p)

MicroRNA-132-3p (miR-132-3p) is a small non-coding RNA that plays a pivotal role in regulating gene expression post-transcriptionally by binding to the 3' untranslated regions of target mRNAs. It is highly expressed in the central nervous system and the heart, where it modulates critical processes such as synaptic plasticity, neurite outgrowth, and cardiomyocyte hypertrophy (PubMed: 17360917, 24614104). In the cardiovascular system, pathological upregulation of miR-132-3p is a key driver of adverse cardiac remodeling and heart failure, primarily through the inhibition of the pro-autophagic transcription factor FoxO3 (PubMed: 24614104, 33495592). Conversely, its downregulation in the brain is associated with neurodegenerative conditions like Alzheimer's disease, where it impacts tau metabolism and neuronal survival (PubMed: 23913180). Therapeutic strategies currently focus on using antisense oligonucleotides, such as CDR132L, to inhibit miR-132-3p in heart failure patients to reverse remodeling and improve cardiac function (ClinicalTrials.gov: NCT05350969). This target represents a novel class of epigenetic modifiers with the potential to address complex multi-genic disease pathways.

Other names

hsa-miR-132-3pmiR-132MIR132MicroRNA 132

Antisense oligonucleotide-mediated inhibition (antagomir) of microRNA function to derepress target messenger RNAs